CAPRICOR THERAPEUTICS, INC. — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Capricor announced July 29, 2026 that The Lancet published results from its pivotal Phase 3 HOPE-3 trial (n=106, randomized, double-blind, placebo-controlled) of Deramiocel for Duchenne muscular dystrophy. The trial met its primary endpoint: Deramiocel slowed upper limb function decline by 54% versus placebo (PUL 2.0, p=0.03) and showed clinically meaningful cardiac benefit. The Deramiocel BLA remains under FDA active review with a PDUFA target action date of August 22, 2026.
Why this rating
Peer-reviewed publication of positive Phase 3 data with FDA decision imminent represents major near-term inflection point for a ~$400M company. Success or rejection would materially alter trajectory.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.